IRVINE, CA -- (Marketwired) -- 02/20/14 -- Masimo (NASDAQ: MASI) today announced that its award-winning iSpO2® pulse oximeter is now available for Android, along with the companion iSpO2 app downloaded from the Google Play Store. With the release of iSpO2 in the popular Android operating system, more consumers than ever now have access to Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry -- the same technology used in leading hospitals worldwide.
iSpO2 provides accurate, real-time oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI) readings -- ideal for anyone who desires access to accurate health data through their mobile devices.
Stig Severinsen, Ph.D. in medicine, a four-time World Champion freediver and owner of multiple Guinness World Records, including history's longest breath-hold of 22 mintues, uses iSpO2 as part of his regimen.
"Training for extreme records under extreme conditions is always a huge challenge," Severinsen said. "In such situations it is of great value to be able to perform noninvasive and accurate measurements of my heart rate and oxygen levels with a state-of-the-art device. Masimo has created a clever device that not only displays your measurements in real time -- even during motion and states of low perfusion in cold conditions -- but it also allows you to store and share data with people in your team.
"I would recommend Masimo's iSpO2 to anyone interested in health and fitness -- understanding what goes on inside your body is paramount to improving performance," he added.
Dr. Mark Hom, M.D., co-author of forthcoming exercise books with three-time Tour de France champion Greg LeMond, and Dr. Glenn A. Gaesser, Ph.D., said: "Although we advocate intense training, we don't recommend that healthy athletes train to the point of oxygen desaturation (i.e., cyanosis). However, our preliminary testing with the iSpO2 has shown that it has the accuracy and repeatability to show subtle changes in athletic oxygenation: specifically in warm-up, steady state, super high intensity, and recovery. And as an added benefit, the iSpO2 is compact enough to be useful when training on the road or track."
"This pulse oximeter is without a doubt the best one available for the consumer market," said Dr. Kirk Shelley, M.D., PhD, professor of anesthesiology at Yale University in New Haven, Conn. "Masimo uses impressive digital signal processing combined with proprietary light emitting diode (LED) technology. If you need a serious pulse oximeter, this is the one to get."
iSpO2 -- extremely lightweight at just 232 grams or about 0.5 pounds -- also displays the pleth waveform and Signal IQ so users can visually assess where the pulse is occurring and the quality of the measurement even during motion artifact. iSpO2 can also trend, store, and email up to 12 hours of measurement history in the global standard .CSV file format, allowing consumers to easily share data through their mobile device email application.
The performance of Masimo SET® pulse oximetry is proven by more than 100 independent and objective studies and thousands of clinical evaluations to accurately monitor blood oxygen saturation even in the most challenging conditions, including patient movement and low peripheral perfusion. The pulse oximetry standard-of-care at leading hospitals worldwide -- including by eight of the top 10 hospitals on the U.S. News & World Report Best Hospitals Honor Roll (2013-2014) -- Masimo SET® virtually eliminates false alarms1 and increases a clinician's ability to detect life-threatening events.2
Please visit iSpO2.com for purchasing information. iSpO2 is for sports and aviation use; not intended for medical use.
Android is a trademark of Google Inc. The Android robot is reproduced or modified from work created and shared by Google and used according to terms described in the Creative Commons 3.0 Attribution License.
1 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91.
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa). Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors related to the iSpO2, including our belief in the breakthrough ability of Masimo SET® pulse oximetry to measure-through motion and low perfusion; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SedLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.
All other trademarks, service marks, trade names, logos and icons, registered or not, are the property of third parties as named/indicated.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2524752